University of Bordeaux, Inserm, Bordeaux, Population Health Research Center, Team SISTM, Bordeaux, France.
INRIA Bordeaux Sud Ouest, Talence, France.
Stat Med. 2019 Jan 30;38(2):221-235. doi: 10.1002/sim.7957. Epub 2018 Sep 26.
In human immunodeficiency virus-infected patients, antiretroviral therapy suppresses the viral replication, which is followed in most patients by a restoration of CD4+ T cells pool. For patients who fail to do so, repeated injections of exogenous interleukin 7 (IL7) are experimented. The IL7 is a cytokine that is involved in the T cell homeostasis and the INSPIRE study has shown that injections of IL7 induced a proliferation of CD4+ T cells. Phase I/II INSPIRE 2 and 3 studies have evaluated a protocol in which a first cycle of three IL7 injections is followed by a new cycle at each visit when the patient has less than 550 CD4 cells/μL. Restoration of the CD4 concentration has been demonstrated, but the long-term best adaptive protocol is yet to be determined. A mechanistic model of the evolution of CD4 after IL7 injections has been developed, which is based on a system of ordinary differential equations and includes random effects. Based on the estimation of this model, we use a Bayesian approach to forecast the dynamics of CD4 in new patients. We propose four prediction-based adaptive protocols of injections to minimize the time spent under 500 CD4 cells/μL for each patient, without increasing the number of injections received too much. We show that our protocols significantly reduce the time spent under 500 CD4 over a period of two years, without increasing the number of injections. These protocols have the potential to increase the efficiency of this therapy.
在人类免疫缺陷病毒(HIV)感染患者中,抗逆转录病毒疗法可抑制病毒复制,大多数患者随后会出现 CD4+T 细胞池的恢复。对于未能达到此效果的患者,会尝试反复注射外源性白细胞介素 7(IL7)。IL7 是一种参与 T 细胞稳态的细胞因子,INSPIRE 研究表明,IL7 注射可诱导 CD4+T 细胞增殖。INSPIRE 2 和 3 期的 I/II 期研究评估了一种方案,该方案包括三个 IL7 注射周期,随后在每次就诊时,如果患者的 CD4 细胞数/μL 小于 550 个,则开始新的周期。已经证明 CD4 浓度得到了恢复,但长期最佳适应方案仍有待确定。已经开发了一种基于 IL7 注射后 CD4 演变的机制模型,该模型基于一个常微分方程系统,并包含随机效应。基于该模型的估计,我们使用贝叶斯方法来预测新患者的 CD4 动态。我们提出了四种基于预测的注射自适应方案,以最大程度地减少每个患者在 CD4 细胞数/μL 低于 500 时所花费的时间,而不会增加太多注射次数。我们表明,我们的方案在两年的时间内显著减少了 CD4 细胞数低于 500 的时间,而没有增加注射次数。这些方案有可能提高该疗法的效率。